ReviewWorld journal of gastrointestinal oncology2021
Radiomics in hepatocellular carcinoma: A state-of-the-art review.
Review in World journal of gastrointestinal oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Patient characteristics to guide personalized treatment decisions and prognostication in hepatocellular carcinoma.Hepatic oncology · 2026Review
- CT-Based Radiomics for Non-Invasive Prediction of Ki-67 Expression in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Article
- Review
- How to Predict Recurrence After Resection of Hepatocellular Carcinoma.Anticancer research · 2025Article
- Magnetic Resonance Imaging Liver Segmentation Protocol Enables More Consistent and Robust Annotations, Paving the Way for Advanced Computer-Assisted Analysis.Diagnostics (Basel, Switzerland) · 2024Article
- A novel radiomics approach for predicting TACE outcomes in hepatocellular carcinoma patients using deep learning for multi-organ segmentation.Scientific reports · 2024Article
- Construction of a 2.5D Deep Learning Model for Predicting Early Postoperative Recurrence of Hepatocellular Carcinoma Using Multi-View and Multi-Phase CT Images.Journal of hepatocellular carcinoma · 2024Article
- Article
- A Review of the Clinical Applications of Artificial Intelligence in Abdominal Imaging.Diagnostics (Basel, Switzerland) · 2023Review
- A multidisciplinary approach with immunotherapies for advanced hepatocellular carcinoma.Journal of liver cancer · 2023Article
- Hepatocellular carcinoma: State of the art diagnostic imaging.World journal of radiology · 2023Review
- Imaging Diagnosis of Hepatocellular Carcinoma: A State-of-the-Art Review.Diagnostics (Basel, Switzerland) · 2023Review
- From imaging to clinical outcome: dual-region CT radiomics predicting FOXM1 expression and prognosis in hepatocellular carcinoma.Frontiers in oncology · 2023Article
- The Role of Radiomics and AI Technologies in the Segmentation, Detection, and Management of Hepatocellular Carcinoma.Cancers · 2022Review
- Current Imaging Diagnosis of Hepatocellular Carcinoma.Cancers · 2022Review
- Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights.Journal of hepatocellular carcinoma · 2022Review
- Foundations of Artificial Intelligence in Hepatology: What a Clinician Needs to Know.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the most common cancer and the second major contributor to cancer-related mortality. Radiomics, a burgeoning technology that can provide invisible high-dimensional quantitative and mineable data derived from routine-acquired images, has enormous potential for HCC management from diagnosis to prognosis as well as providing contributions to the rapidly developing deep learning methodology. This article aims to review the radiomics approach and its current state-of-the-art clinical application scenario in HCC. The limitations, challenges, and thoughts on future directions are also summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.